 |
Keynote Speakers: JOEL ACKERMAN Joel Ackerman is a General Partner and a Managing Director of Warburg Pincus, and a member of the firm’s Executive Management Group. He joined the firm in 1993 and has always focused on investing in the healthcare services sector. Mr. Ackerman received a B.A. in physics from Columbia University and an M.A. in physics from Harvard University. Prior to joining Warburg Pincus he was with Mercer Management Consulting. He is a director of ChartOne, CCS Medical, Coventry Health Care, Medical Staffing Network and Spheris.
MARK BLATT, MD Dr. Blatt joined Intel in the summer of 2000 in the company’s New Business Group. He is currently the Director for Global Healthcare Strategies in the Digital Health Group. Prior to this, Dr. Blatt served for 3 years as the Manager for Worldwide Healthcare Strategies in the Sales and Marketing Group. During this time he played a key role in formulating Intel’s Integrated Digital Hospital vision. This vision has gained significant momentum and mindshare with Intel’s healthcare customers, fellow travellers, and industry thought leaders worldwide. He has also worked on a variety of health related Internet business efforts, including a platform to deliver home-based medical care. Prior to joining Intel he was the managing partner of a five-provider group of family practitioners. He practiced family medicine for 15 years before returning to Yale University to earn his MBA (2000) in finance. Dr. Blatt earned his Medical Doctorate at Albany Medical College of Union University (1979). He completed a residency in Family Practice at the University of Connecticut (1982). He then served two years as a Commissioned Officer in the US Public Health Service before starting private practice. He is a member of the IEEE Medical Technology Policy Committee, the American Telemedicine Association, and a diplomat of the American Board of Family Practice. STANLEY BREZENOFF Stanley Brezenoff was named President and Chief Executive Officer of Continuum Health Partners in July 2003. In this position, Mr. Brezenoff oversees the partnership of four venerable health care providers in New York City: Beth Israel Medical Center, St. Luke’s-Roosevelt Hospital Center, Long Island College Hospital and New York Eye and Ear Infirmary. Continuum delivers care through nearly 3,100 certified beds in seven major hospital facilities throughout Manhattan and Brooklyn, and through group and private practice settings and ambulatory centers in Manhattan, Brooklyn, the Bronx and Westchester County. The hospital system maintains an annual operating budget of $2.3 billion, employs over 16,000 individuals (the fifth largest employer in the metropolitan area) and provides a home base for over 5,000 affiliated physicians. Prior to joining Continuum, Mr. Brezenoff served as President and Chief Executive Officer of Maimonides Medical Center, a 705-bed tertiary care teaching hospital in Brooklyn, New York—a position he held from February 1995 to June 2003. From 1990 to 1995, Mr. Brezenoff was Executive Director of the Port Authority of New York and New Jersey, a public-sector corporation that operates the world’s largest complex of trade and transportation facilities, including the World Trade Center. In 1990, he also served as Senior Program Advisor for the Commonwealth Fund, a philanthropic institution with a particular focus on health care. Mr. Brezenoff’s career in New York City public service began in 1978 when he was appointed Commissioner for the Department of Employment and later as Administrator of the Human Resources Administration. From 1981 to 1984, Mr. Brezenoff was President of the New York City Health and Hospitals Corporation (HHC), which governs the world’s largest non-federal health care system. In 1984, Mayor Edward Koch asked Mr. Brezenoff to serve as Deputy Mayor for Operations and then as First Deputy Mayor of the City of New York. In that position, he directed the day-to-day operations of city agencies, including Police, Fire, Sanitation, Parks, Transportation, Corrections, Juvenile Justice, Probation, Human Resources, Health, and Aging. During that time, he was also a member of the Metropolitan Transportation Authority Board, mayoral liaison to the Board of Education and City University of New York (CUNY), as well as Chairman of HHC. Prior to his appointments in city government, from 1969 to 1978 Mr. Brezenoff served as Program Officer for the Ford Foundation in its National Affairs, Government & Law and Social Policy Divisions. He was responsible for the Foundation’s $10 million program in non-judicial conflict resolution and a host of other programs, including an income security project that provided information for policy makers in the welfare field. Before joining the Foundation, Mr. Brezenoff was active in the Congress of Racial Equality and the Citywide Committee for Integrated Schools. Mr. Brezenoff has served as Program Advisor for the New York Urban Coalition and he has served as Chairman of the Board of Directors of Healthfirst, the League of Voluntary Hospitals & Homes of New York, New York Academy of Medicine (NYAM), Dean’s Council of New York University Robert F. Wagner School of Public Service and the Greater New York Hospital Association (GNYHA). Mr. Brezenoff is currently the President of Initiative for a Competitive Brooklyn, a board member of the Healthcare Association of New York State (HANYS), The September 11th Fund, Academic Medicine Development Company (AMDeC) and Structured Employment and Economic Development Corporation (SEEDCO). Mr. Brezenoff was born in Brooklyn and received his Bachelor of Arts Degree in Philosophy from Brooklyn College. Stanley Brezenoff will be interviewed by Tim Race TIM RACE Tim Race is the Health Care Editor in the business section of The New York Times. Mr. Race came to The Times in 1989 as a story editor for The Business World, a quarterly supplement to The New York Times Magazine. He joined the paper’s financial news department in 1991, where over the years he has served as the information technology editor and the media editor. In 1997 he helped conceive and design The Times’ weekly consumer-technology section, Circuits, and was a founding editor of the section when it made its debut in February 1998. He then returned to the financial news department to oversee the Monday section. His essays and articles about technology have appeared in The Times, The New York Times Magazine and The Industry Standard. Before coming to The Times, Mr. Race was an editor at CMP Publications Inc. in Manhasset, N.Y., where his posts included executive editor of CommunicationsWeek. Earlier in his career, he taught ethnomusicology and trumpet at the University of Nigeria. Mr. Race has a master’s degree in journalism and public affairs from American University, Washington, D.C. (1983), and a master’s in popular culture from Bowling Green State University in Ohio (1980). His bachelor’s degree is in interdisciplinary studies from Miami University, Oxford, Ohio (1978). G. STEVEN BURRILL G. Steven Burrill is Chief Executive Officer of Burrill & Company, a San Francisco based life sciences firm focused exclusively on companies involved in biotechnology, pharmaceuticals, diagnostics, devices, human healthcare and related medical technologies, nutraceuticals and wellness, agricultural biotechnology, and industrial biotechnology (biomaterials/bioprocesses). Burrill & Company’s business revolves around three core activities: Venture Capital, Merchant Banking and Media. In these activities, Burrill & Company seeks to create value through developing significant equity stakes in its portfolio companies which benefit from Burrill & Company’s unparalleled network in the life science community. In addition to the company’s staff of over 50, Burrill & Company calls upon the members of its advisory boards for counsel. These boards are composed of former chief executives of major pharmaceutical, and biotech companies; industry luminaries; world-renowned scientists; and Nobel Laureates. The Burrill family of venture capital funds, with over $500 million under management, includes the Burrill Life Sciences Capital Fund, the Burrill Biotechnology Capital Fund, the Burrill Agbio Capital Fund and its successor—the Burrill Agbio Capital Fund II, and the Burrill Nutraceuticals Capital Fund. Burrill & Company has commenced raising its Burrill Life Sciences Capital Fund III, a $300-500 million fund, which it expects to close in 2005 Mr. Burrill has devoted his career to helping life science companies launch their operations and sustain their growth in the face of a constant and rapidly changing environment. In 2002, he was recognized as the biotech investment visionary by the prestigious Scientific American magazine (The Scientific American 50). He currently serves as Chairman of the Boards of Icoria (NASDAQ: ICOR), Pharmasset and Pyxis Genomics; and is a member of the Boards of Directors of Catalyst Biosciences, DepoMed (Amex: DMI) and Targacept. Mr. Burrill is a founder of The Biotech Meeting at Laguna Niguel (now in its 18th year); The Life Sciences Partnering Meeting; C21 BioVentures (formerly The Life Sciences Ventures Conference), The Japan Biotech Meeting, and The Midwest Life Sciences Meeting. These annual events enable Burrill & Company to remain on the cutting edge of the industry to maintain strong ties with the leading companies, CEOs, and the most promising technologies—making Burrill & Company the “best networked” company in the industry. Prior to founding Burrill & Company in 1994, Mr. Burrill spent 28 years with Ernst & Young (through 1993) directing and coordinating the firm’s services to clients in the biotechnology/life sciences and high technology/manufacturing industries worldwide. He was the International Chairman of the Life Sciences/Biotechnology and Manufacturing/High Technology practices (responsible for approximately one-third of the firm’s then $6.5 billion business). His E&Y experience included working with ALZA, Amgen, Calgene, Chiron (Cetus), Collagen, Corixa (Anergen), Genentech, Gilead Sciences, InSite Vision, SciClone, Sequus (now part of ALZA), and Terrapin from their inception. As an internationally recognized spokesman for the life sciences and high technology industries, Mr. Burrill has authored a variety of articles and books about the business, management and financial concerns of life science, high tech and high growth companies. He is a regular columnist for BioPharm, American Genomics and Proteomics Technology, and The Journal of BioLaw and Business and serves on the Advisory Editorial Board of BioPeople. In addition, Mr. Burrill has authored annual reports on the US and European biotechnology industry for the last 19 years. Biotech 2005—Life Sciences: A Move Towards Predictability is Mr. Burrill’s newest edition. In addition to his work with leading life science companies, Mr. Burrill also chaired the National Research Council study on linkages in biotechnology between Japan and the United States. He was also involved with the US-Japan Science and Technology Agreement Study of Technology Transfer Mechanisms between the US and Japan. Mr. Burrill is a founder of the Foundation for the National Medals of Science and Technology and currently serves on its Board of Directors. In addition, he serves on the Board of Directors for the Bay Area Science Infrastructure Consortium, BayBio, the California Healthcare Institute, the Exploratorium, the Kellogg Center for Biotechnology, Research!America, Campaign for Medical Research (Chairman) and the University of California, San Francisco (UCSF) Foundation. He also serves on the Advisory Boards for BioExecutive, BioProcess, Hadasit, MIT Center for Biomedical Innovation (CBI), Campaign for Public Health, Science and Mathematics Initiative (SMI), and the University of Hawaii Medical School, as well as serving as Chairman of the San Francisco Mayor’s Biotechnology Advisory Council (MayBAC). In addition, he is a member of The World Bank’s “Out of the Box” group as well as an adjunct professor at UCSF. Mr. Burrill earned his BBA in accounting and finance from the University of Wisconsin in Madison. He and his family make their home in San Francisco CHAD FLOE Charles P. (“Chad”) Floe joined the Corporate Finance & Origination (CFO) business of Dresdner Kleinwort Wasserstein (DrKW), the investment bank of Dresdner Bank AG, as a Managing Director and Head of the Healthcare sector group in July 2003. He is based in London with global responsibility for CF&O healthcare and is a member of the Operating Committee of CFO, with broader management responsibilities for the global TMT, Chemicals, and General Industrials sectors. Prior to joining DrKW, Chad was at Lehman Brothers in London where he was also a Managing Director in Corporate Finance and Head of International Healthcare (with responsibility for this sector outside of North America). He was at Lehman for over ten years, starting there in 1992. Earlier, he worked at First Boston Corporation (1986-1992) in both London and New York, and JP Morgan (1981-1984) in New York. Chad has advised on a wide variety of healthcare transactions, including M&A and financings, for a variety of pharmaceutical, bio-technology, agricultural chemical and biotechnology, medical technology and healthcare service company clients.
|
|
|
New York, NY November 29, 2005
|
